Eric Jonasch News Today

Eric Jonasch, MD, discusses the goals of a meeting sponsored by the International Kidney Cancer Coalition that will focus on patient advocacy in GU malignancies.

An expert discusses three crucial conversations about cancer care that patients should have with their health care providers.

Eric Jonasch, MD, discusses the evolution of belzutifan in cancer care, highlighting the agent’s potential for the treatment of patients with renal cell carcinoma.

Researchers continue to investigate novel immunotherapy drugs for the treatment of renal cell carcinoma.

Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.

Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism.

MD Anderson researchers are driven by a shared goal to end cancer. Here are 22 of their most impactful accomplishments from this past year.

When cancer is detected at an early stage, the rates of survival increase drastically, but today only a few cancer types are screened for. 

When cancer is detected at an early stage, the rates of survival increase drastically, but today only a few cancer types are screened for.

/PRNewswire/ -- Vial introduces a new member joining their Oncology CRO Advisory Board. Eric Jonasch, MD, is a Genitourinary Medical Oncology Professor and...